<p>根據 S&amp;P 全球市場情報的數據，<strong>Hims &amp; Hers</strong>(HIMS 1.74%) 的股票本週下跌了 17%。該遠程醫療平台正在實現巨大的收入增長，但面臨與減肥藥製造商的法律糾紛風險。該股票的價格比歷史最高點下跌了 25%，但由於平台的快速增長，過去五年上漲了 400%。</p>
<p>以下是本週股票下跌的原因。</p>
<h2>快速增長但面臨訴訟</h2>
<p>在 2025 年第二季度，Hims &amp; Hers 的收入同比增長 73%，超過 5 億美元，使其成為全球增長最快的公司之一。這得益於 Hims &amp; Hers 產品的總訂閲用户增長 30% 以及每位活躍用户的消費增長 30%。該公司提供基本藥品的遠程醫療服務，如脱髮、性健康和減肥藥。</p>
<p>儘管公司快速增長並且現在實現了盈利，但 Hims &amp; Hers 正面臨與 <strong>諾和諾德</strong> 的法律糾紛。減肥藥的創新者最初與 Hims &amp; Hers 建立了合作關係，但因對 Hims &amp; Hers 銷售其減肥藥配方的仿製品存在分歧而退出了交易。Hims &amp; Hers 在短缺期間被允許銷售專利減肥藥，但現在短缺已結束，銷售專利藥物給客户並提供折扣的行為已違反法律。</p>
<p>毫不奇怪，Hims &amp; Hers 因這一做法而被起訴，而這一做法正是其業務快速增長的一部分。投資者對這場法律糾紛的未來影響感到擔憂，擔心這可能會損害 Hims &amp; Hers 未來的收入增長和盈利能力。</p>
<p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84Mjg3MjYvaGVhbHRoY2FyZS5qcGcmdz03MDA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84Mjg3MjYvaGVhbHRoY2FyZS5qcGcmdz03MDA"/></p>
<p>圖片來源：Getty Images。</p>
<h2>你應該購買 Hims &amp; Hers 的股票嗎？</h2>
<p>在過去幾年中，Hims &amp; Hers 的股票表現出色，使股東們獲得了豐厚的回報。它的收入達到 20 億美元，過去五年增長超過 1000%。毫無疑問，它是互聯網藥物和醫療治療的領先遠程醫療提供商，在過去幾年中在市場份額上取得了巨大的進展。</p>
<p>如果沒有法律糾紛，Hims &amp; Hers 可能會在這次下跌中成為一個值得購買的股票。然而，我們不能忽視潛在的法律後果以及 Hims &amp; Hers 管理層通過公然在其網站上銷售專利減肥藥而給自己和股東帶來的巨大風險。這場法律糾紛不太可能有好的結果。在與減肥藥製造商的爭端解決之前，不要在 Hims &amp; Hers 的股票上抄底。</p>

HIMS

<p>Hims & Hers 的股票本週下跌了 17%，較歷史最高點下跌了 25%，儘管 2025 年第二季度的收入增長達 73%。該遠程醫療平台正面臨與 Novo Nordisk 的法律糾紛，涉及銷售專利減肥藥物，這引發了對未來收入和盈利能力的擔憂。儘管公司經歷了顯著增長，但建議投資者在法律問題解決之前不要購買該股票，因為這些問題對其業務構成了重大風險</p>

<p>Shares of <strong>Hims &amp; Hers</strong>(HIMS 1.74%) stock sank 17% this week, according to data from S&amp;P Global Market Intelligence. The telehealth platform is delivering huge revenue growth but is at risk of a legal battle with weight loss drugmakers. Shares of the stock are down 25% from all-time highs but are up 400% in the past five years due to the platform's fast growth.</p>
<div class="lb-trans"><p>根據 S&amp;P 全球市場情報的數據，<strong>Hims &amp; Hers</strong>(HIMS 1.74%) 的股票本週下跌了 17%。該遠程醫療平台正在實現巨大的收入增長，但面臨與減肥藥製造商的法律糾紛風險。該股票的價格比歷史最高點下跌了 25%，但由於平台的快速增長，過去五年上漲了 400%。</p>
</div><p>Here's why the stock sank this week.</p>
<div class="lb-trans"><p>以下是本週股票下跌的原因。</p>
</div><h2>Fast growth but a looming lawsuit</h2>
<div class="lb-trans"><h2>快速增長但面臨訴訟</h2>
</div><p>In the second quarter of 2025, Hims &amp; Hers' revenue grew 73% year over year to over $500 million, making it one of the fastest-growing companies in the world. This was driven by 30% growth in total subscribers to Hims &amp; Hers products and 30% growth in spend per active subscriber. The company offers telehealth services for basic pharmaceuticals such as hair loss, sexual wellness, and weight loss drugs.</p>
<div class="lb-trans"><p>在 2025 年第二季度，Hims &amp; Hers 的收入同比增長 73%，超過 5 億美元，使其成為全球增長最快的公司之一。這得益於 Hims &amp; Hers 產品的總訂閲用户增長 30% 以及每位活躍用户的消費增長 30%。該公司提供基本藥品的遠程醫療服務，如脱髮、性健康和減肥藥。</p>
</div><p>While the company is growing quickly and now generating a profit, Hims &amp; Hers is facing a looming legal battle with <strong>Novo Nordisk</strong>. The innovator in weight loss drugs originally had a partnership with Hims &amp; Hers but pulled out of the deal because of disagreements over Hims &amp; Hers selling knockoffs of its weight loss drug formula. Hims &amp; Hers was permitted to sell patented weight loss drugs while they were in shortage, but now that the shortage is over, it is breaking the law by selling patented drugs to customers at a discount.</p>
<div class="lb-trans"><p>儘管公司快速增長並且現在實現了盈利，但 Hims &amp; Hers 正面臨與 <strong>諾和諾德</strong> 的法律糾紛。減肥藥的創新者最初與 Hims &amp; Hers 建立了合作關係，但因對 Hims &amp; Hers 銷售其減肥藥配方的仿製品存在分歧而退出了交易。Hims &amp; Hers 在短缺期間被允許銷售專利減肥藥，但現在短缺已結束，銷售專利藥物給客户並提供折扣的行為已違反法律。</p>
</div><p>Unsurprisingly, Hims &amp; Hers is getting sued for this practice, which is a fast-growing part of its business. Investors are worried about the future impacts of this legal battle and how it could hurt Hims &amp; Hers' future revenue growth and profitability.</p>
<div class="lb-trans"><p>毫不奇怪，Hims &amp; Hers 因這一做法而被起訴，而這一做法正是其業務快速增長的一部分。投資者對這場法律糾紛的未來影響感到擔憂，擔心這可能會損害 Hims &amp; Hers 未來的收入增長和盈利能力。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84Mjg3MjYvaGVhbHRoY2FyZS5qcGcmdz03MDA" alt="" original-src="https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F828726%2Fhealthcare.jpg&amp;op=resize&amp;w=700"/></p>
<p>Image source: Getty Images.</p>
<div class="lb-trans"><p>圖片來源：Getty Images。</p>
</div><h2>Should you buy Hims &amp; Hers stock?</h2>
<div class="lb-trans"><h2>你應該購買 Hims &amp; Hers 的股票嗎？</h2>
</div><p>Hims &amp; Hers has been an incredible stock to own over the last few years, making shareholders rich. It has $2 billion in trailing revenue, up over 1,000% in the last five years. By far, it is the leading telehealth provider for drugs and medical treatments over the internet, making a ton of inroads in market share gains in the last few years.</p>
<div class="lb-trans"><p>在過去幾年中，Hims &amp; Hers 的股票表現出色，使股東們獲得了豐厚的回報。它的收入達到 20 億美元，過去五年增長超過 1000%。毫無疑問，它是互聯網藥物和醫療治療的領先遠程醫療提供商，在過去幾年中在市場份額上取得了巨大的進展。</p>
</div><p>If there were no legal battle looming, Hims &amp; Hers would probably be a buy on this dip. However, we cannot ignore the potential legal ramifications and <em>huge risk</em> Hims &amp; Hers management is putting on itself and shareholders by blatantly selling patented weight loss drugs on its website. This legal battle is not likely to end well. Don't buy the dip on Hims &amp; Hers stock until its dispute with the weight loss drugmakers is resolved.</p>
<div class="lb-trans"><p>如果沒有法律糾紛，Hims &amp; Hers 可能會在這次下跌中成為一個值得購買的股票。然而，我們不能忽視潛在的法律後果以及 Hims &amp; Hers 管理層通過公然在其網站上銷售專利減肥藥而給自己和股東帶來的巨大風險。這場法律糾紛不太可能有好的結果。在與減肥藥製造商的爭端解決之前，不要在 Hims &amp; Hers 的股票上抄底。</p>
</div>

為什麼 Hims & Hers Health 的股票本週下跌